8HHH
![Download](/newweb/media/icons/dl.png) ![Visualize](/newweb/media/icons/hoh_3d.png)
![BU of 8hhh by Molmil](/molmil-images/mine/8hhh) | |
8HHG
![Download](/newweb/media/icons/dl.png) ![Visualize](/newweb/media/icons/hoh_3d.png)
![BU of 8hhg by Molmil](/molmil-images/mine/8hhg) | |
8HHF
![Download](/newweb/media/icons/dl.png) ![Visualize](/newweb/media/icons/hoh_3d.png)
![BU of 8hhf by Molmil](/molmil-images/mine/8hhf) | |
7YCK
![Download](/newweb/media/icons/dl.png) ![Visualize](/newweb/media/icons/hoh_3d.png)
![BU of 7yck by Molmil](/molmil-images/mine/7yck) | Crystal structure of SARS-CoV-2 Spike RBD in complex with FP-12A Fab | 分子名称: | 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-[alpha-L-fucopyranose-(1-6)]2-acetamido-2-deoxy-beta-D-glucopyranose, FP-12A Fab heavy chain, FP-12A Fab light chain, ... | 著者 | Nguyen, V.H.T, Chen, X. | 登録日 | 2022-07-01 | 公開日 | 2023-02-01 | 最終更新日 | 2023-11-29 | 実験手法 | X-RAY DIFFRACTION (2.6 Å) | 主引用文献 | Structural basis for a conserved neutralization epitope on the receptor-binding domain of SARS-CoV-2. Nat Commun, 14, 2023
|
|
8YRP
![Download](/newweb/media/icons/dl.png) ![Visualize](/newweb/media/icons/hoh_3d.png)
![BU of 8yrp by Molmil](/molmil-images/mine/8yrp) | SARS-CoV-2 Delta Spike in complex with JM-1A | 分子名称: | JM-1A Heavy Chain, JM-1A Light Chain, Spike glycoprotein | 著者 | Nguyen, V.H.T, Chen, X. | 登録日 | 2024-03-21 | 公開日 | 2024-06-05 | 最終更新日 | 2024-06-26 | 実験手法 | ELECTRON MICROSCOPY (3.64 Å) | 主引用文献 | The presence of broadly neutralizing anti-SARS-CoV-2 RBD antibodies elicited by primary series and booster dose of COVID-19 vaccine. Plos Pathog., 20, 2024
|
|
8YRO
![Download](/newweb/media/icons/dl.png) ![Visualize](/newweb/media/icons/hoh_3d.png)
![BU of 8yro by Molmil](/molmil-images/mine/8yro) | SARS-CoV-2 Delta Spike in complex with JL-8C | 分子名称: | JL-8C Heavy Chain, JL-8C Light Chain, Spike glycoprotein | 著者 | Nguyen, V.H.T, Chen, X. | 登録日 | 2024-03-21 | 公開日 | 2024-06-05 | 最終更新日 | 2024-06-26 | 実験手法 | ELECTRON MICROSCOPY (3.27 Å) | 主引用文献 | The presence of broadly neutralizing anti-SARS-CoV-2 RBD antibodies elicited by primary series and booster dose of COVID-19 vaccine. Plos Pathog., 20, 2024
|
|